These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33025951)

  • 21. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.
    Cicero AFG; Fogacci F; Hernandez AV; Banach M;
    PLoS Med; 2020 Jul; 17(7):e1003121. PubMed ID: 32673317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
    Agarwala A; Quispe R; Goldberg AC; Michos ED
    Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis.
    Masson W; Lobo M; Lavalle-Cobo A; Molinero G
    Clin Investig Arterioscler; 2021; 33(3):117-126. PubMed ID: 33328138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bempedoic acid for the treatment of hypercholesterolemia.
    Yang J
    Expert Rev Cardiovasc Ther; 2020 Jul; 18(7):373-380. PubMed ID: 32532162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bempedoic acid: mechanism of action].
    Corsini A; Scicchitano P
    G Ital Cardiol (Rome); 2021 Apr; 22(4 Suppl 1):9S-14S. PubMed ID: 33847313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bempedoic Acid: for Whom and When.
    Ruscica M; Sirtori CR; Carugo S; Banach M; Corsini A
    Curr Atheroscler Rep; 2022 Oct; 24(10):791-801. PubMed ID: 35900636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
    Feng X; Zhang L; Xu S; Shen AZ
    Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
    Pinkosky SL; Newton RS; Day EA; Ford RJ; Lhotak S; Austin RC; Birch CM; Smith BK; Filippov S; Groot PHE; Steinberg GR; Lalwani ND
    Nat Commun; 2016 Nov; 7():13457. PubMed ID: 27892461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
    Burke AC; Huff MW
    Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.
    Lemus HN; Mendivil CO
    J Clin Lipidol; 2015; 9(3):384-9. PubMed ID: 26073398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of bempedoic acid on markers of inflammation and Lp(a).
    Reddy S; Deoker A
    Curr Opin Cardiol; 2024 Jul; 39(4):280-285. PubMed ID: 38456474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How Will Our Practice Change After the CLEAR Outcomes Trial?
    Abrahams T; Nelson AJ; Nicholls SJ
    Curr Atheroscler Rep; 2024 Mar; 26(3):83-89. PubMed ID: 38294660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
    Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
    J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).
    Ballantyne CM; Banach M; Bays HE; Catapano AL; Laufs U; Stroes ESG; Robinson P; Lei L; Ray KK
    Am J Cardiol; 2022 Jul; 174():1-11. PubMed ID: 35483979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia.
    Schimmenti C; Sucato V; Manzone E; Cancellieri G; Mortillaro F; Novo G; Galassi AR; Venturella F
    Coron Artery Dis; 2021 Jun; 32(4):340-344. PubMed ID: 33229935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
    Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
    JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid.
    Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T
    J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia.
    Wichaiyo S; Supharattanasitthi W
    Clin Drug Investig; 2021 Oct; 41(10):843-851. PubMed ID: 34435333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.